Compare GSK plc (GSK) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs TKO Group Holdings Inc — how do they compare? GSK plc trades at $52.39 (market cap $101.34B), while TKO Group Holdings Inc trades at $181.06 (market cap $13.92B). The key difference: GSK plc is far larger — about 7.3× TKO Group Holdings Inc's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | TKO | |
|---|---|---|
Market Cap | $101.34B | $13.92B |
Sector | Health | Technology |
52-Week High | $61.18 | $224.96 |
52-Week Low | $36.20 | $155.61 |
Enterprise Value | $121.95B | $18.10B |
Dividend Yield | 3.49% | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
TKO trades at $182.03, down 1.37% on the day, with a bearish technical signal from moving averages. The company reported mixed quarterly earnings, missing in Q3 and Q4 2025 but beating in Q1 2026. Revenue grew to $4.74B in 2025, with a net income margin of 4.47%. Recent developments include a successful $800 million share repurchase and strong UFC event viewership, while an insider sale of $1.8 million shares occurred in July 2026.
The outlook is supported by analyst consensus with a $228.40 price target and 89% buy ratings, but high valuation multiples like a P/E of 69.03 pose risks. Key opportunities include live event demand growth and partnership expansions, while execution risks and market volatility remain concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
